Cancer Therapy-Related Cardiac Dysfunction: A Review of Current Trends
Author Information
Author(s): Theofilis Panagiotis, Vlachakis Panayotis K., Oikonomou Evangelos, Drakopoulou Maria, Karakasis Paschalis, Apostolos Anastasios, Pamporis Konstantinos, Tsioufis Konstantinos, Tousoulis Dimitris
Primary Institution: 1st Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens, Greece
Hypothesis
How do cancer therapies impact cardiac health?
Conclusion
The review highlights the importance of early detection and interdisciplinary collaboration in managing cancer therapy-related cardiac dysfunction.
Supporting Evidence
- Cancer therapies like anthracyclines can lead to heart problems.
- Early detection using biomarkers can help prevent serious heart issues.
- Interdisciplinary collaboration between oncologists and cardiologists is crucial for patient care.
- Preventive strategies can reduce the risk of cardiac dysfunction in cancer patients.
Takeaway
Cancer treatments can hurt the heart, but doctors can find problems early and help keep patients safe while treating their cancer.
Methodology
The review summarizes existing evidence on the mechanisms, detection methods, and treatments for cancer therapy-related cardiac dysfunction.
Limitations
The review may not cover all cancer therapies and their cardiovascular effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website